全文获取类型
收费全文 | 2969篇 |
免费 | 150篇 |
国内免费 | 99篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 37篇 |
妇产科学 | 7篇 |
基础医学 | 224篇 |
口腔科学 | 32篇 |
临床医学 | 129篇 |
内科学 | 219篇 |
皮肤病学 | 18篇 |
神经病学 | 24篇 |
特种医学 | 150篇 |
外科学 | 295篇 |
综合类 | 373篇 |
预防医学 | 318篇 |
眼科学 | 4篇 |
药学 | 943篇 |
中国医学 | 206篇 |
肿瘤学 | 234篇 |
出版年
2024年 | 5篇 |
2023年 | 60篇 |
2022年 | 106篇 |
2021年 | 121篇 |
2020年 | 95篇 |
2019年 | 101篇 |
2018年 | 116篇 |
2017年 | 109篇 |
2016年 | 86篇 |
2015年 | 108篇 |
2014年 | 196篇 |
2013年 | 229篇 |
2012年 | 154篇 |
2011年 | 182篇 |
2010年 | 136篇 |
2009年 | 154篇 |
2008年 | 143篇 |
2007年 | 177篇 |
2006年 | 119篇 |
2005年 | 128篇 |
2004年 | 108篇 |
2003年 | 89篇 |
2002年 | 67篇 |
2001年 | 59篇 |
2000年 | 55篇 |
1999年 | 38篇 |
1998年 | 28篇 |
1997年 | 20篇 |
1996年 | 23篇 |
1995年 | 29篇 |
1994年 | 33篇 |
1993年 | 23篇 |
1992年 | 15篇 |
1991年 | 17篇 |
1990年 | 9篇 |
1989年 | 16篇 |
1988年 | 14篇 |
1987年 | 16篇 |
1986年 | 3篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1972年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有3218条查询结果,搜索用时 15 毫秒
1.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
2.
3.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献4.
Matthew D. Li Katrina F. Chu Allegra DePietro Vincent Wu Eric Wehrenberg-Klee Omar Zurkiya Raymond W. Liu Suvranu Ganguli 《Journal of vascular and interventional radiology : JVIR》2019,30(3):314-319
Purpose
To evaluate the feasibility of a same-day yttrium-90 (90Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases.Materials and Methods
All same-day radioembolization procedures performed over 1 y (February 2017 to January 2018) were included in this single-institutional retrospective analysis, in which 34 procedures were performed in 26 patients (median age, 63 y; 13 women), 19 with liver metastases and 7 with HCC. Yttrium-90 treatment activities were calculated by body surface area method. Tumor imaging response was assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for liver metastases and modified RECIST for HCC. Clinical side effects and adverse events were graded per Common Terminology Criteria for Adverse Events version 4.0.Results
All planned cases were technically successful, and no cases were canceled for elevated LSF or vascular anatomic reasons. Pretreatment angiography modified the planned 90Y treatment activity in 1 case in which vascular anatomy required a lobar-dose split into 2 for segmental infusions. In 18% of cases, patients were briefly admitted after the procedure for observation or symptom management. Imaging evaluation of initial efficacy at 1 month demonstrated partial response in 25% and stable disease in 67% of patients with liver metastases and partial/complete response in 43% and stable disease in 14% of patients with HCC. Grade ≥ 3 adverse events occurred in 6% of cases, with no systemic therapy–limiting toxicities. The mean total procedure time was 4.2 hours.Conclusions
A same-day 90Y radioembolization protocol with resin microspheres is feasible in select patients, which can expedite cancer therapy. 相似文献5.
根据3.7 L瑞士Bioengineer KLF2000型发酵罐分批发酵的实验数据,利用GraphPad Prism软件对假单胞菌BS-03产鼠李糖脂生物表面活性剂的发酵动力学模型进行非线性拟合,说明Logistic模型和L-P模型能较好的描述假单胞菌BS-03发酵过程中的菌体生长、鼠李糖脂合成和限制性基质的消耗动力学。 相似文献
6.
从内蒙古呼伦贝尔草原的盐碱湖中分离到的一株低度嗜盐嗜碱细菌Bacillus sp F26,能积累高水平过氧化氢酶(CAT)。对Bacillus sp F26发酵产过氧化氢酶的环境与营养条件的研究结果表明,其积累高水平过氧化氢酶的适宜环境条件为:温度37℃,种龄20-22h,接种量5%,装液量50mL/(250mL的摇瓶)。适宜发酵培养基组成(g/L)为:葡萄糖15,牛肉膏10,玉米浆10,酵母膏5,磷酸二氢钾1,氯化镁0.2,氯化钠50,碳酸钠10。采用上述条件进行摇瓶分批发酵实验,发酵20h,过氧化氢酶酶活达到16.32U/mL,细胞干重为4.12g/L。进一步研究发现,在对数生长后期(16h)添加2mmol/L的H2O2可以明显刺激产酶,在5L的发酵罐上进一步以指数速率方式流加H2O2,由于该流加方式可降低H2O2对细胞的毒害作用,过氧化氢酶酶活达到29.89U/mL,与分批发酵相比提高了92.8%。 相似文献
7.
从芫花Daphne genkwa条的乙酸乙酯可溶部分分到3个结果性化合物,借助于波谱分析手段推断出Ⅱ为西瑞香素,Ⅲ为daphnodorin B。 相似文献
8.
灵芪菌质发酵工艺初报 总被引:2,自引:0,他引:2
目的:探讨灵芪菌质发酵的工艺,验证药用真菌新型固体发酵的优越性.方法:将灵芝分别在普通基质、药性基质(含黄芪)、富硒药性基质中发酵,对三种基质中菌质的有效部位多糖的含量进行测定及动态研究,比较其变化.结果:三种基质中菌质有效部位多糖含量及其相对标准差分别为4.65%、1.61%,3.76%、1.99%,4.50%、1.86%;对灵芝和黄芪发酵组合的有效成分多糖、蛋白质及总皂苷进行动态变化研究,发现第28天是发生次生代谢最旺盛的时候,确定为发酵终点.结论:灵芝和黄芪发酵组合是可行的. 相似文献
9.
通过酸性平板筛选,在作者所在实验室保藏的运动发酵单胞菌中,得到一株能在pH4.5时进行酒精发酵的菌株,其酒精产量为66.7g/L,与原菌株在pH6.5时的相同.通过单因素实验和正交实验,对该菌在酸性条件下的酒精发酵条件进行了优化.结果表明,在发酵温度为30~35℃,pH4.5,初糖质量浓度150g/L,酵母膏质量浓度4g/L,蛋白胨质量浓度为2g/L时,该菌的酒精产量达到最大,为71.7g/L. 相似文献
10.
p. jouët j.-m. sabaté e. cuillerier † b. coffin m. lémann ‡ r. jian † & b. flourié § 《Neurogastroenterology and motility》2006,18(1):45-52
Lactulose (10-20 g day(-1)) is used to treat constipation. At this therapeutic dose, its effects on colonic motility remain unknown. Twenty-two healthy subjects swallowed a probe with an infusion catheter, six perfused catheters and a balloon connected to a barostat. Colonic phasic and tonic motor activity was recorded in fasting state. In group 1, four volunteers ingested 15 g lactulose and motility was recorded for 5 h after entry of lactulose into the caecum; in group 2, motility was recorded during (3 h) and 2 h after intracolonic infusion of isoosmotic and isovolumetric solutions containing sodium chloride alone (n = 9) or with 15 g lactulose (n = 9). In a last group of volunteers, isotopic colonic transit after ingestion of lactulose (10 g,n = 9) was assessed and compared with a control group (n = 17). Ingestion or intracolonic infusion of 15 g lactulose significantly decreased barostat bag volume (maximal decrease: 45 +/- 12% and 35 +/- 9% of basal value respectively). Phasic contractions remained unchanged. Tonic and phasic motility was unchanged by the isotonic and isovolumetric infusion of saline. Ingestion of lactulose significantly accelerated isotopic colonic transit time compared with the control group. We conclude that in healthy humans, 10-15 g ingestion or intracaecal infusion of lactulose produces a prolonged tonic contraction that may be involved in the laxative effect of lactulose. 相似文献